Marcaine 0,5 % Adrénaline

Bupivacaine hydrochloride, the active ingredient in Marcaine 0,5 % Adrénaline, is a local anesthetic presented as a 0.5% solution for epidural and infiltration use. It provides regional anesthesia for surgical procedures and pain management.

GNH USA supplies Marcaine 0,5 % Adrénaline as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marcaine 0,5 % Adrénaline, a combination local anesthetic, is employed in clinical situations that require regional nerve block or analgesia.

- Surgical procedures: provides local anesthesia for incision and operative sites. - Epidural analgesia: delivers pain relief during labor or postoperative periods. - Infiltration anesthesia: numbs tissue for minor surgeries or dental procedures.

Common side effects are generally mild and transient.

Common Side Effects: - Transient pain at injection site - Tachycardia - Hypertension - Nausea - Dizziness

Serious or Rare Side Effects: - Cardiac arrhythmias - Seizures - Severe hypotension - Allergic reactions (anaphylaxis)

When using Marcaine 0,5 % Adrénaline, clinicians should observe several safety measures.

- Allergy assessment: verify no known hypersensitivity to bupivacaine, epinephrine or amide‑type anesthetics. - Cardiovascular status: avoid in patients with uncontrolled hypertension or arrhythmias. - Dosage limits: adhere to recommended maximum dose to prevent toxicity. - Concurrent MAO inhibitors: use with caution as epinephrine effects may be enhanced. - Pregnancy and lactation: assess risk–benefit; limited data are available. - Store at ambient temperature: keep in original container, protect from light and moisture.

Marcaine 0,5 % Adrénaline may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Beta‑blockers: may potentiate epinephrine‑induced hypertension and tachycardia. - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiac toxicity with bupivacaine. - Monoamine oxidase inhibitors (MAOIs): can amplify epinephrine effects.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may affect cardiac conduction when combined with bupivacaine. - Other local anesthetics: additive toxicity risk. - Sympathomimetic drugs (e.g., phenylephrine): monitor blood pressure.